🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchEfinopegdutide — what worked for you? Page 3

Efinopegdutide — what worked for you?

marcus_mpls Sun, Aug 4, 2024 at 3:39 PM 14 replies 2,111 viewsPage 3 of 3
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Aug 6, 2024 at 3:03 AM#11
sophie_paris said:
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to: Point estimate (HR/RR/OR) —…

Fair, and it stops being fair at the extremes. The middle of the range is well understood; the ends are where the honest answer is that nobody knows.

22 20julia.endo, JessicaM_2024, TomFromTexas and 19 others
Reply Quote Save Share Report
SteveThurs
Member
523
2,345
Sep 2024
Wisconsin
Online
Aug 6, 2024 at 5:41 AM#12
CryptoCarl said:
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals.

That reframing is the part I needed.

Last edited: Aug 6, 2024 at 9:41 AM
23 21PurityPaulOR, MaxMetOK, MounjBrad and 20 others
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Aug 6, 2024 at 8:19 AM#13
sophie_paris said:
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to: Point estimate (HR/RR/OR) —…

Pushing back on sophie_paris here. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

24 22Dr.SleepRoch, laura_annarbor, JenMemphis and 21 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Aug 6, 2024 at 10:56 AM#14

One concrete data point for the thread. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

25 23DebRD_ATL, KristenIndy, MarkLI_maint and 22 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Aug 6, 2024 at 1:33 PM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Report rather than reply if it drifts again.

26 24PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 23 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register